Last updated: September 29, 2026
Sorbitan monopalmitate, commonly sold as Span 40 or sorbitan palmitate, is a nonionic, lipophilic surfactant used primarily as a water-in-oil emulsifier, wetting agent, dispersant, and stabilizer. Its pharmaceutical market is a niche within the broader excipients and specialty surfactants sectors. Public companies generally do not report revenue for sorbitan monopalmitate separately, so financial analysis depends on end-market demand, raw-material costs, formulation activity, and supplier-grade economics rather than audited product-level sales.
The product has a mature core chemistry, limited standalone patent exposure, and relatively low substitution barriers in some formulations. Its strongest commercial position is in applications requiring a low-HLB emulsifier with established regulatory histories, controlled impurity profiles, and reliable supply.
What is sorbitan monopalmitate and how is it used?
Sorbitan monopalmitate is an ester of sorbitan and palmitic acid. It is also known as sorbitan palmitate, Span 40, and by Chemical Abstracts Service number 26266-58-0. Commercial material can contain related sorbitan esters and reaction byproducts because the manufacturing process produces an ester distribution rather than a single perfectly defined molecular species.
| Attribute |
Description |
| Common name |
Sorbitan monopalmitate |
| Trade name |
Span 40 |
| CAS number |
26266-58-0 |
| Chemical class |
Sorbitan fatty-acid ester |
| Surfactant type |
Nonionic, lipophilic |
| Typical HLB value |
Approximately 6.7 |
| Primary function |
Emulsifier, dispersant, wetting agent, stabilizer |
| Main formulation preference |
Water-in-oil and low-HLB emulsions |
| Related materials |
Sorbitan monooleate, sorbitan monostearate, polysorbate 20, polysorbate 60, polysorbate 80 |
| Regulatory identity |
Often listed as sorbitan palmitate or sorbitan monopalmitate |
Sorbitan monopalmitate is generally paired with a higher-HLB surfactant when a formulation requires a balanced emulsifier system. The combination can improve interfacial stability, droplet-size control, and consistency across storage conditions. Its function depends heavily on oil phase composition, processing temperature, water activity, particle size, and the presence of co-emulsifiers.
What pharmaceutical formulations use sorbitan monopalmitate?
The principal pharmaceutical uses are topical, semisolid, oral, and specialty delivery formulations. Use is usually driven by formulation performance rather than by the active ingredient itself.
Topical and dermatological products
Sorbitan monopalmitate can support creams, ointments, lotions, and other emulsified topical products. Its low-HLB profile is relevant to water-in-oil systems, which can provide occlusion and improve the feel or residence time of a formulation.
Potential functions include:
- Emulsification of oil and aqueous phases
- Stabilization of creams and ointments
- Control of spreading and skin feel
- Dispersion of lipophilic actives
- Support for controlled release from semisolid bases
Topical demand is commercially important because manufacturers often retain established excipient systems after scale-up. Once an excipient is embedded in a validated product, substitution can require compatibility, stability, microbial, process, and regulatory work.
Oral solid and lipid-based formulations
Sorbitan monopalmitate may be used in tablets, capsules, lipid-based delivery systems, and dispersions where wetting or dispersion of hydrophobic ingredients is required. Its use is generally formulation-specific. It is not a universal substitute for polysorbates, sodium lauryl sulfate, poloxamers, or more hydrophilic surfactants.
In lipid-based oral delivery, the relevant commercial value is often linked to the complete excipient system rather than the individual surfactant. Demand can rise when pharmaceutical developers pursue formulations for poorly water-soluble compounds, modified release, or improved content uniformity.
Nutraceutical and food applications
Sorbitan monopalmitate is also used in food applications under the designation E495 in jurisdictions where permitted. Food-grade demand can exceed pharmaceutical demand in some supply chains, but the two markets require different documentation, specifications, impurity controls, and quality systems. A supplier may sell the same basic chemistry into both markets while maintaining separate grades.
How large is the sorbitan monopalmitate market?
No major public company routinely discloses standalone revenue for sorbitan monopalmitate. Market reports usually aggregate the material into one or more of the following categories:
- Food emulsifiers
- Nonionic surfactants
- Pharmaceutical excipients
- Specialty chemicals
- Sorbitan esters
- Cosmetic emulsifiers
This aggregation makes product-level market-size estimates unreliable. A defensible financial view should therefore use market proxies instead of assigning an unsupported global revenue figure.
The addressable market is driven by five factors:
| Driver |
Effect on demand |
| Growth in topical pharmaceuticals |
Supports emulsifier consumption |
| Development of lipid-based drug delivery |
Supports specialty formulation demand |
| Generic and contract manufacturing activity |
Supports recurring validated-excipient purchases |
| Food and personal-care demand |
Provides volume diversification |
| Regulatory and supply-chain qualification |
Favors established, documented suppliers |
The pharmaceutical portion is likely higher value per kilogram than food-grade material because customers pay for documentation, batch consistency, audit support, traceability, and change-control management. Volume growth does not necessarily translate into equivalent revenue growth because large customers can negotiate commodity-style pricing.
What is the financial trajectory for sorbitan monopalmitate?
The financial trajectory is best characterized as mature, volume-sensitive, and margin-divided by grade.
Base-case trajectory
A reasonable base case is low-to-moderate volume growth with stable demand from established formulations. Revenue expansion would likely come from:
- Increased pharmaceutical and nutraceutical production.
- New topical and lipid-based delivery systems.
- Greater use of documented excipient grades in regulated markets.
- Supply-chain diversification outside single-country sourcing.
Pricing growth is less certain. Sorbitan monopalmitate is an established chemistry with multiple alternative emulsifiers. This limits the supplier’s ability to pass through cost inflation unless the product is sold with a differentiated pharmaceutical grade, technical support package, or validated supply status.
Cost structure
The principal cost inputs are likely to include:
- Palmitic acid and related fatty-acid feedstocks
- Sorbitol and sorbitan intermediates
- Energy for esterification and purification
- Packaging and hazardous or controlled transport requirements
- Quality-control testing
- Regulatory documentation and customer audits
Feedstock exposure creates margin volatility. Palmitic acid prices are influenced by vegetable-oil markets, palm-oil economics, oleochemical capacity, freight, and regional energy costs. Suppliers with integrated or long-term oleochemical sourcing can have a cost advantage.
Margin segmentation
| Product category |
Typical commercial profile |
| Technical grade |
Higher volume, lower price, more direct substitution |
| Food grade |
Volume-oriented, specification-sensitive |
| Cosmetic grade |
Formulation and sensory-performance focus |
| Pharmaceutical grade |
Lower volume, higher documentation burden and unit value |
| Custom or micronized grade |
Higher margin, lower scale, application-specific |
The most attractive margin pool is generally the regulated grade sold under a quality agreement. The least defensible margin pool is undifferentiated technical material, where buyers can compare suppliers on price and basic specification.
Which companies supply sorbitan monopalmitate?
The commercial supply base includes large specialty-chemical companies, excipient distributors, laboratory suppliers, and regional manufacturers. Croda is associated with the Span range, including Span 40. Other companies may offer sorbitan palmitate under generic or distributor brands.
| Supplier category |
Commercial role |
| Global specialty-chemical producer |
Consistent manufacturing, regulatory support, multinational supply |
| Pharmaceutical excipient producer |
GMP-oriented documentation and qualification support |
| Chemical distributor |
Regional inventory and smaller customer access |
| Laboratory supplier |
Research quantities, not necessarily commercial-scale supply |
| Contract manufacturer |
Custom specification, packaging, or regional production |
Supplier selection is typically determined by more than price. Pharmaceutical customers evaluate residual solvents, acid value, saponification value, hydroxyl value, water content, peroxide value, elemental impurities, microbial quality, allergen status, TSE/BSE declarations, and change-control procedures. The exact test panel varies by grade and intended use.
What regulatory status does sorbitan monopalmitate have?
Sorbitan monopalmitate has established use histories in food, cosmetics, and pharmaceutical formulations, but regulatory status is jurisdiction- and application-specific.
The U.S. Food and Drug Administration’s Inactive Ingredient Database is a key reference for determining whether an excipient has precedent in approved drug products. An FDA IID listing does not constitute blanket approval for every route, dose, dosage form, or quality grade. Sponsors must still demonstrate suitability in the proposed formulation and comply with applicable current good manufacturing practice requirements. [1]
In Europe, sorbitan palmitate is recognized within the food-additive framework where applicable, including the E495 designation. Food authorization does not automatically establish pharmaceutical acceptability. Pharmaceutical use depends on product-specific quality, safety, and regulatory assessment. [2]
Relevant compendial and quality considerations may include:
- Identity and assay
- Acid value
- Saponification value
- Hydroxyl value
- Water content
- Residual solvents
- Elemental impurities
- Microbial quality
- Oxidative stability
- Fatty-acid composition
- Batch-to-batch ester distribution
The European Chemicals Agency and other chemical regulators treat sorbitan ester substances within broader chemical-safety frameworks. Those requirements affect manufacture, importation, worker safety, and environmental compliance rather than drug approval directly. [3]
What patents protect sorbitan monopalmitate?
The core sorbitan monopalmitate molecule is an old chemical entity. Broad composition-of-matter patent protection for the molecule is not a meaningful current barrier to entry. The commercially relevant intellectual-property risks are more likely to involve:
- Manufacturing processes
- Purification methods
- Narrow impurity specifications
- Particular particle-size distributions
- Co-processed excipient systems
- Combination emulsifier systems
- Drug formulations containing sorbitan monopalmitate
- Delivery systems using the excipient with a specific active ingredient
A formulation patent may claim a pharmaceutical composition containing sorbitan monopalmitate, but that claim does not necessarily prevent production or sale of the excipient itself. Patent exposure should therefore be assessed at the product and application level, not by treating the excipient as a single patent-controlled asset.
There is no conventional Orange Book exclusivity framework for sorbitan monopalmitate as an excipient. It is not an active pharmaceutical ingredient with listed drug patents. Paragraph IV challenges, generic drug litigation, and biosimilar competition are not normally directed at the excipient molecule.
How strong is the intellectual-property position for suppliers?
Supplier IP strength is likely to be moderate in process know-how and low in the basic chemical composition.
| IP area |
Likely strength |
| Core molecule |
Low |
| Basic esterification process |
Low to moderate |
| Proprietary purification |
Moderate |
| Pharmaceutical-grade specifications |
Moderate, often protected through know-how and quality systems |
| Co-processed systems |
Moderate to high if technically differentiated |
| Drug-specific formulation |
Potentially high, but owned by the drug developer |
| Trade secrets and process controls |
Material commercial value |
The most durable competitive advantage is usually operational rather than patent-based. It includes reproducible ester composition, low impurity levels, reliable documentation, validated sites, dual sourcing, and the ability to support regulatory audits.
What manufacturing barriers affect sorbitan monopalmitate?
Manufacturing is technically established but quality consistency is important. Esterification can generate related sorbitan esters, unreacted fatty acids, unesterified sorbitan derivatives, color bodies, and process-related impurities. The commercial specification must control composition and performance, not merely nominal chemical identity.
Key barriers include:
- Consistent fatty-acid feedstock quality
- Control of reaction temperature and catalyst conditions
- Removal of unreacted materials
- Oxidation control
- Reproducible HLB and emulsification performance
- Scale-up without changes in ester distribution
- Pharmaceutical-grade cleaning and documentation
- Supply continuity for critical raw materials
The principal manufacturing risk is not whether the chemistry can be performed. It is whether the supplier can reproduce the same functional behavior across batches and production sites.
How does sorbitan monopalmitate compare with competing emulsifiers?
| Excipient |
Relative profile |
Common advantage |
| Sorbitan monopalmitate |
Low-HLB, lipophilic |
Water-in-oil emulsification |
| Sorbitan monostearate |
Low-HLB, higher melting behavior |
Cream and ointment structure |
| Sorbitan monooleate |
Low-HLB, liquid-oil compatibility |
Flexible lipid-phase processing |
| Polysorbate 20 |
High-HLB, hydrophilic |
Oil-in-water systems and solubilization |
| Polysorbate 60 |
High-HLB |
Emulsification with higher fatty-acid content |
| Polysorbate 80 |
High-HLB, widely used |
Solubilization and biologic formulation support |
| Poloxamers |
Amphiphilic block copolymers |
Solubilization and temperature-responsive systems |
| Lecithin |
Natural phospholipid mixture |
Liposomal and parenteral applications |
Sorbitan monopalmitate is most defensible where a low-HLB profile, oil-phase compatibility, and established formulation history matter. It is less competitive when the formulation requires strong water solubilization, high-HLB emulsification, or biologic-protein stabilization.
What generic entry and commercial risks exist?
The material does not face generic entry in the same way as a finished pharmaceutical product. Instead, commercial risk comes from substitution and supplier switching.
The main risks are:
- Reformulation toward polysorbates or poloxamers
- Use of alternative sorbitan esters
- Customer consolidation of excipient suppliers
- Qualification of lower-cost regional manufacturers
- Feedstock price inflation
- Regulatory changes affecting fatty-acid sources
- Batch failures or changes in ester distribution
- Loss of a major topical or food customer
Switching costs are higher for approved pharmaceutical products than for laboratory or early-stage formulations. A supplier with a large installed base in commercial products has more defensible recurring revenue than a supplier selling only development quantities.
What is the five-year commercial outlook?
The outlook is stable rather than high-growth. Demand should track broader expansion in topical pharmaceuticals, specialty generics, nutraceuticals, cosmetics, and lipid-based delivery systems. The best revenue opportunities are likely to come from pharmaceutical-grade material, dual-sourced supply programs, and technical support for formulation development.
The principal limitations are product maturity, substitute availability, and weak standalone pricing power. Suppliers that compete only on bulk volume may experience margin pressure. Suppliers that provide consistent pharmaceutical grades, regulatory files, regional inventory, and formulation support should capture a larger share of the value pool.
Key Takeaways
- Sorbitan monopalmitate, or Span 40, is a mature nonionic surfactant with a low-HLB profile.
- Its core uses are water-in-oil emulsification, dispersion, wetting, and stabilization.
- Pharmaceutical demand is concentrated in topical, semisolid, oral lipid-based, and specialty formulations.
- No reliable public standalone market size or product-level revenue series is generally available.
- Financial performance depends on grade mix, palmitic-acid costs, qualification status, and supplier documentation.
- Core molecule patent protection is not a material entry barrier.
- Process know-how, quality systems, impurity control, and supply reliability are more important than composition patents.
- The product has no conventional Orange Book, Paragraph IV, or biosimilar exposure.
- Long-term growth is likely to be modest, with better margins in pharmaceutical-grade and customized supply programs.
FAQs about sorbitan monopalmitate
Is sorbitan monopalmitate the same as Span 40?
Yes. Span 40 is a common commercial name for sorbitan monopalmitate or sorbitan palmitate. Commercial grades can contain related sorbitan esters and must be evaluated against the supplier’s specification.
Is sorbitan monopalmitate safe for pharmaceutical use?
It has established use histories, but suitability depends on route, dose, grade, formulation, and jurisdiction. An FDA inactive-ingredient listing or food authorization does not replace product-specific regulatory assessment.
Can sorbitan monopalmitate be used in injectable drugs?
Injectable use requires specific regulatory and toxicological support. The fact that the substance is used in topical, oral, food, or cosmetic products does not establish acceptability for parenteral administration.
What is the difference between sorbitan monopalmitate and polysorbate 80?
Sorbitan monopalmitate is a low-HLB, lipophilic surfactant suited to oil-rich and water-in-oil systems. Polysorbate 80 is a high-HLB surfactant used more often for oil-in-water emulsions, solubilization, and stabilization of certain biologic formulations.
Which factors determine sorbitan monopalmitate pricing?
Pricing depends on grade, order volume, regional inventory, fatty-acid feedstock costs, packaging, testing requirements, GMP documentation, and whether the customer requires a qualified pharmaceutical supply chain.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Parliament and Council of the European Union. (2008). Regulation (EC) No 1333/2008 on food additives. EUR-Lex. https://eur-lex.europa.eu/
-
European Chemicals Agency. (n.d.). Substance information: Sorbitan palmitate. https://echa.europa.eu/
-
United States Pharmacopeial Convention. (2025). United States Pharmacopeia and National Formulary. USP.
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Sorbitan palmitate. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
Croda International Plc. (n.d.). Span surfactants and emulsifiers: Technical information. https://www.croda.com/
